NASDAQ:GLYC GlycoMimetics (GLYC) Stock Price, News & Analysis → 3 Dirt-Cheap Stocks You Can’t Afford to Ignore (From TradingTips) (Ad) Free GLYC Stock Alerts $0.30 +0.02 (+7.16%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.28▼$0.3150-Day Range$0.26▼$3.1852-Week Range$0.26▼$3.53Volume2.71 million shsAverage Volume3.80 million shsMarket Capitalization$19.30 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get GlycoMimetics alerts: Email Address GlycoMimetics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside3,240.0% Upside$10.00 Price TargetShort InterestBearish9.45% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.63) to ($0.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.63 out of 5 starsMedical Sector236th out of 921 stocksPharmaceutical Preparations Industry98th out of 426 stocks 3.0 Analyst's Opinion Consensus RatingGlycoMimetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageGlycoMimetics has only been the subject of 2 research reports in the past 90 days.Read more about GlycoMimetics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.45% of the outstanding shares of GlycoMimetics have been sold short.Short Interest Ratio / Days to CoverGlycoMimetics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in GlycoMimetics has recently increased by 102.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlycoMimetics does not currently pay a dividend.Dividend GrowthGlycoMimetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlycoMimetics has received a 73.56% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for GlycoMimetics is -0.55. Previous Next 1.7 News and Social Media Coverage News SentimentGlycoMimetics has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for GlycoMimetics this week, compared to 1 article on an average week.Search InterestOnly 22 people have searched for GLYC on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.MarketBeat Follows9 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GlycoMimetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.70% of the stock of GlycoMimetics is held by insiders.Percentage Held by Institutions75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GlycoMimetics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for GlycoMimetics are expected to grow in the coming year, from ($0.63) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GlycoMimetics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlycoMimetics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlycoMimetics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about GlycoMimetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad TradingTips3 Dirt-Cheap Stocks You Can’t Afford to Ignore Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.Get your FREE look at these THREE companies right here. About GlycoMimetics Stock (NASDAQ:GLYC)GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Read More GLYC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLYC Stock News HeadlinesMay 15 at 5:27 AM | americanbankingnews.comStockNews.com Initiates Coverage on GlycoMimetics (NASDAQ:GLYC)May 10, 2024 | msn.comGlycoMimetics GAAP EPS of -$0.17 in-lineMay 9, 2024 | msn.comGlycoMimetics Q1 2024 Earnings PreviewMay 9, 2024 | americanbankingnews.comCapital One Financial Comments on GlycoMimetics, Inc.'s Q1 2024 Earnings (NASDAQ:GLYC)May 9, 2024 | americanbankingnews.comGlycoMimetics (NASDAQ:GLYC) Cut to "Equal Weight" at Capital One FinancialMay 9, 2024 | americanbankingnews.comHC Wainwright Comments on GlycoMimetics, Inc.'s Q1 2024 Earnings (NASDAQ:GLYC)May 8, 2024 | markets.businessinsider.comSell Rating on Lyra Therapeutics Amid Phase 3 Study Failure and Funding ConcernsMay 8, 2024 | americanbankingnews.comGlycoMimetics (NASDAQ:GLYC) Rating Reiterated by HC WainwrightMay 7, 2024 | msn.comHC Wainwright & Co. Downgrades GlycoMimetics (GLYC)May 6, 2024 | msn.comGlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares SinkMay 6, 2024 | markets.businessinsider.comWhy Is GlycoMimetics Stock Falling In Pre-market?May 6, 2024 | marketwatch.comGlycoMimetics Shares Drop After Leukemia Treatment Trial Fails to Meet Primary EndpointMay 6, 2024 | businesswire.comGlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)April 28, 2024 | finance.yahoo.comWe're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn RateApril 27, 2024 | finance.yahoo.comGlycoMimetics, Inc. (GLYC)April 25, 2024 | businesswire.comGlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024April 15, 2024 | money.usnews.comGlycoMimetics IncApril 1, 2024 | finance.yahoo.comLoss-Making GlycoMimetics, Inc. (NASDAQ:GLYC) Expected To Breakeven In The Medium-TermMarch 28, 2024 | finance.yahoo.comGlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | markets.businessinsider.comPositive Outlook for GlycoMimetics: Buy Rating Affirmed Amid Anticipated Pivotal Trial Results and Strategic Growth InitiativesMarch 28, 2024 | finance.yahoo.comQ4 2023 GlycoMimetics Inc Earnings CallMarch 27, 2024 | markets.businessinsider.comBuy Rating on GlycoMimetics Backed by Strong Financials and Promising Phase 3 Trial of UproleselanMarch 27, 2024 | markets.businessinsider.comBuy Recommendation for GlycoMimetics Based on Promising Upro Drug Prospects and Strong PipelineMarch 27, 2024 | investorplace.comGLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023March 27, 2024 | sfgate.comGlycoMimetics: Q4 Earnings SnapshotSee More Headlines Receive GLYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today5/17/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GLYC CUSIPN/A CIK1253689 Webwww.glycomimetics.com Phone(240) 243-1201Fax301-738-2137Employees35Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$12.00 Low Stock Price Target$8.00 Potential Upside/Downside+3,240.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,900,000.00 Net MarginsN/A Pretax Margin-372,770.03% Return on Equity-88.40% Return on Assets-76.65% Debt Debt-to-Equity RatioN/A Current Ratio6.28 Quick Ratio6.41 Sales & Book Value Annual Sales$10,000.00 Price / Sales1,929.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book0.67Miscellaneous Outstanding Shares64,460,000Free Float58,856,000Market Cap$19.30 million OptionableOptionable Beta2.30 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Harout Semerjian (Age 54)CEO, President & Director Comp: $1.13MMs. Rachel K. King (Age 65)Co-Founder & Director Comp: $40kMr. Brian M. Hahn (Age 50)Senior VP & CFO Comp: $822.12kDr. Edwin Rock M.D. (Age 63)Ph.D., Senior VP & Chief Medical Officer Comp: $677.4kMs. Stephanie R. Irish CPA (Age 53)Vice President of Accounting Mr. Christian B. Dinneen-LongGeneral Counsel & Company SecretaryMr. Bruce Johnson (Age 56)Senior VP & Chief Commercial Officer Mr. Chinmaya Rath (Age 47)Senior VP & Chief Business Officer Mr. Shantha Tyavanagimatt Ph.D.Senior Vice President of Technical OperationsMore ExecutivesKey CompetitorsMinerva NeurosciencesNASDAQ:NERVTalpheraNASDAQ:TLPHVBI VaccinesNASDAQ:VBIVGalectoNASDAQ:GLTOAytu BioPharmaNASDAQ:AYTUView All CompetitorsInsiders & InstitutionsIkarian Capital LLCBought 172,800 shares on 5/17/2024Ownership: 0.000%NEA Management Company LLCSold 929,401 shares on 5/15/2024Ownership: 5.949%Affinity Asset Advisors LLCBought 142,300 shares on 5/15/2024Ownership: 0.000%Vanguard Group Inc.Bought 340,112 shares on 5/10/2024Ownership: 4.285%Acadian Asset Management LLCSold 210,650 shares on 5/10/2024Ownership: 0.513%View All Insider TransactionsView All Institutional Transactions GLYC Stock Analysis - Frequently Asked Questions Should I buy or sell GlycoMimetics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GLYC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLYC, but not buy additional shares or sell existing shares. View GLYC analyst ratings or view top-rated stocks. What is GlycoMimetics' stock price target for 2024? 2 brokers have issued twelve-month price objectives for GlycoMimetics' shares. Their GLYC share price targets range from $8.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 3,240.0% from the stock's current price. View analysts price targets for GLYC or view top-rated stocks among Wall Street analysts. How have GLYC shares performed in 2024? GlycoMimetics' stock was trading at $2.36 at the start of the year. Since then, GLYC stock has decreased by 87.3% and is now trading at $0.2994. View the best growth stocks for 2024 here. When is GlycoMimetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our GLYC earnings forecast. How were GlycoMimetics' earnings last quarter? GlycoMimetics, Inc. (NASDAQ:GLYC) posted its quarterly earnings data on Wednesday, March, 27th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. The biotechnology company had revenue of $0.01 million for the quarter. What other stocks do shareholders of GlycoMimetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX). Who are GlycoMimetics' major shareholders? GlycoMimetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (5.95%), Vanguard Group Inc. (4.29%), Acadian Asset Management LLC (0.51%), Ikarian Capital LLC (0.00%), Affinity Asset Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Brian M Hahn, Bruce S Johnson, Daniel M Junius, Edwin Rock, John L Magnani, Patricia S Andrews, Public Equities LP Invus and Scott D Sandell. View institutional ownership trends. How do I buy shares of GlycoMimetics? Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLYC) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubThe Presidential candidate you should REALLY be worried aboutStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
